Inmune Bio, Inc.
Clinical trials sponsored by Inmune Bio, Inc., explained in plain language.
-
Alzheimer's drug study ends early: what happened?
Disease control TerminatedThis study looked at the long-term safety of a drug called XPro1595 in people with Alzheimer's disease who had already finished earlier studies. Only 11 people took part, and the study was stopped early. The main goal was to check for side effects and see if the drug helped with …
Phase: PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control TerminatedThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Phase: PHASE1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:02 UTC
-
COVID-19 drug trial halted: did INB03 help High-Risk patients avoid ICU?
Disease control TerminatedThis study tested a drug called INB03 in 79 high-risk COVID-19 patients to see if it could stop their lung problems from getting worse. Participants had conditions like older age, obesity, or heart disease. The trial was stopped early, so results are limited.
Phase: PHASE2, PHASE3 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC